ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2262

Albumin-hitchhiking MMP13 siRNA Conjugate (siMMP13< (EG18L)2) for the Treatment of Rheumatic Disease
Abstract Number: 2263

Nanotherapeutic Approaches for the Treatment of Post-traumatic Osteoarthritis
Abstract Number: 2264

Dysregulated Interferon Gamma Signals Promote Systemic Autoimmunity in STAT1 Gain of Function Syndrome
Abstract Number: 2265

Autoimmune RNA Dysregulation and Seizures: Therapeutic Prospects in Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 2266

Platelet-selectin Prime Lupus Neutrophils to Produce Mitochondrial ROS and Participate in SLE Pathogenesis
Abstract Number: 2267

Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 Interferons in Cutaneous Lupus
Abstract Number: 2268

Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Abstract Number: 2269

Anti-NET Antibodies in Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Abstract Number: 2270

Evidence for Mitochondrial Dysfunction in Blood-derived Endothelial Colony Forming Cells Isolated from Patients with Antiphospholipid Syndrome
Abstract Number: 2271

Circulating Calprotectin: A Potential New Biomarker for “Non-Criteria” Clinical Manifestations of Antiphospholipid Syndrome
Abstract Number: 2272

Temporal Trends in COVID-19 Outcomes Among Patients with Systemic Autoimmune Rheumatic Diseases: From the First Wave to Omicron
Abstract Number: 2273

Waning Vaccine Response After Primary Vaccine Series: Results from the Covid19 Vaccine Response in Rheumatology Patients (COVER) Study
Abstract Number: 2274

Factors Associated with Disease Flare Following SARS-CoV-2 Vaccination in People with Inflammatory Rheumatic and Musculoskeletal Diseases – Results from the Physician-Reported EULAR Coronavirus Vaccine (COVAX) Registry
Abstract Number: 2275

Three Dose SARS-CoV-2 Vaccination Is Associated with Reduced Risk of Breakthrough COVID-19 During Omicron Wave in Patients with Autoimmune Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].